ArticleTargeted oncology2026
Risk of Recurrence in Patients with HR+/HER2- Early Breast Cancer: A Podcast.
Article in Targeted oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Within 20 years of diagnosis, up to 27% of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer will experience recurrence, despite standard-of-care treatments. Of these recurrences, approximately half will occur within 5 years of diagnosis, regardless of disease stage or nodal status. The majority of recurrences are metastatic, for which there is currently no cure. Patients may not fully discern the incurable and potentially distant nature of disease recurrences, or they may be unaware the risk of recurrence exists. Gaps remain in awareness, understanding, and communication around recurrence risk between healthcare professionals and patients. Thus, in addition to understanding the clinical trial and real-world data on recurrences, it is also important to amplify the patient perspective on the impact of recurrence risk to facilitate effective shared decision making. This podcast will bring together physician and patient advocate experts to discuss the risk of recurrence for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer including early and late risk of recurrence, discuss how risk is assessed, and examine the evolving treatment landscape for reducing risk. Supplementary file1 (MP4 310486 KB).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.